Journal
MOLECULAR NEUROBIOLOGY
Volume 59, Issue 6, Pages 3485-3503Publisher
SPRINGER
DOI: 10.1007/s12035-022-02800-y
Keywords
Endocannabinoid system; Cannabidiol; Dimethyl fumarate; Major depressive disorder; Bipolar disorder; Schizophrenia
Categories
Funding
- NHMRC Senior Principal Research Fellowship
- Alfred Deakin Postdoctoral Research Fellowship
- Multiple Sclerosis Research Australia
Ask authors/readers for more resources
This paper investigates the potential origins and mechanisms of endocannabinoid system (ECS) dysfunction in major neuropsychiatric disorders. It explores the effects of inflammation and oxidative stress on ECS and suggests that cannabidiol and dimethyl fumarate may have therapeutic potential for mental illnesses.
The endocannabinoid system (ECS) is composed of the endocannabinoid ligands anandamide (AEA) and 2-arachidonoylgycerol (2-AG), their target cannabinoid receptors (CB1 and CB2) and the enzymes involved in their synthesis and metabolism (N-acyltransferase and fatty acid amide hydrolase (FAAH) in the case of AEA and diacylglycerol lipase (DAGL) and monoacylglycerol lipase (MAGL) in the case of 2-AG). The origins of ECS dysfunction in major neuropsychiatric disorders remain to be determined, and this paper explores the possibility that they may be associated with chronically increased nitro-oxidative stress and activated immune-inflammatory pathways, and it examines the mechanisms which might be involved. Inflammation and nitro-oxidative stress are associated with both increased CB1 expression, via increased activity of the NADPH oxidases NOX4 and NOX1, and increased CNR1 expression and DNA methylation; and CB 2 upregulation via increased pro-inflammatory cytokine levels, binding of the transcription factor Nrf2 to an antioxidant response element in the CNR2 promoter region and the action of miR-139. CB1 and CB2 have antagonistic effects on redox signalling, which may result from a miRNA-enabled negative feedback loop. The effects of inflammation and oxidative stress are detailed in respect of AEA and 2-AG levels, via effects on calcium homeostasis and phospholipase A(2) activity; on FAAH activity, via nitrosylation/nitration of functional cysteine and/or tyrosine residues; and on 2-AG activity via effects on MGLL expression and MAGL. Finally, based on these detailed molecular neurobiological mechanisms, it is suggested that cannabidiol and dimethyl fumarate may have therapeutic potential for major depressive disorder, bipolar disorder and schizophrenia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available